- RESEARCHERS CREATE MINI LIGHT-SENSING RETINA.
Researchers at Johns Hopkins recently
reported that they have created a 3-D complement of human retinal tissue in the laboratory, which includes functioning photoreceptor cells capable of responding to light. The achievement emerged from experiments with human-induced pluripotent stem cells and could eventually enable genetically engineered retinal cell transplants that halt or even reverse a patient's march toward blindness, the researchers say. Read the online
article in the journal Nature Communications.
- POSITIVE INTERIM TOP-LINE CLINICAL RESULTS ANNOUNCED FROM PHASE II STUDY OF SQUALAMINE EYE DROPS FOR WET AMD. Ohr Pharmaceuticals recently
announced positive top-line interim results for its randomized, double-masked, placebo-controlled Phase II clinical trial (Study OHR-002) of squalamine eye drops used in combination with Lucentis p.r.n. for the treatment of wet age-related macular degeneration. The data demonstrated a positive benefit in visual function across multiple clinically relevant endpoints, including a mean change in visual acuity at the end of study visit for the interim analysis group of +10.4 letters with squalamine eye drops plus Lucentis p.r.n. versus +6.3 letters in the placebo eye drops plus Lucentis p.r.n. arm, a 65% additional relative benefit (p=0.18). The squalamine-treated group demonstrated improved best-corrected visual acuity gains relative to the placebo group at all time points evaluated from four to 38 weeks. Ohr plans to present the full data from this interim analysis in the second half of this year, with final clinical trial data expected in the first quarter of 2015.
- RESULTS OF PHASE IIb STUDY OF ROCLATAN REPORTED.
Aerie Pharmaceuticals Inc. shared results of its Phase IIb trial for once-daily, quadruple-action Roclatan. The drug is a combination of the company's triple-action Rhopressa with the prostaglandin analogue latanoprost and the 28-day clinical trial included 297 patients. Roclatan achieved its primary efficacy endpoint of statistically significant superiority over each of its components on day 29. The baseline intraocular pressures tested in the study ranged from 22 mmHg to 36 mmHg. Roclatan lowered mean diurnal IOP on day 29 from 25.1 mmHg at baseline to 16.5 mmHg. Roclatan mean diurnal IOP reduction on day 29 was approximately 2 mmHg greater than latanoprost. Additionally, Roclatan efficacy exceeded that of latanoprost by 1.6 mmHg to 3.2 mmHg across each time point evaluated during the study (8 a.m., 10 a.m., 4 p.m. on days eight, 15 and 29). These results were statistically significant at all time points with p values <0.05. For more highlights of the study results, click
- BAUSCH + LOMB LAUNCHES NEW EYE DROP, RECEIVES FDA CLEARANCE FOR DAILY DISPOSABLE MULTIFOCAL CONTACT LENS.
Bausch + Lomb has announced the availability of Soothe Xtra Protection (XP) eye drops with Restoryl, a unique emulsion system featuring a proprietary blend of mineral oils and interfacial molecules. The company says the drops target the main source of dry-eye symptoms by replenishing the lipid layer of the tear film. The product is preserved with polyquaternium-1 (PQ1) and has a borate buffer system. Soothe XP is now available at Walmart and will be available in Target in July. Additional retailers will follow in the coming months.
Bausch + Lomb also recently reported that the FDA has issued marketing clearance for Biotrue ONEday for Presbyopia (nesofilcon A) soft contact lens, the first daily disposable multifocal contact lens from the Biotrue ONEday family of products. Featuring a next-generation 3-Zone Progressive design, along with bio-inspired HyperGel material, the new lens provides comfortable vision throughout the day, and offers near, intermediate and distance vision. Read more Bausch + Lomb news
- AIR OPTIX COLORS NOW AVAILABLE.
Alcon unveiled Air Optix Colors prescription contact lenses, a new color contact lens that encapsulates the company's 3-in-1 Color Technology in a silicone hydrogel lens. Available in nine colors, Air Optix Colors contact lenses are the first monthly replacement, daily wear color lenses available in the United States on a silicone hydrogel platform, allowing up to six times more oxygen through the contact lens compared to the leading, older technology color contact lens. The lenses are available in prescription and plano form to consumers through their eye-care professional. According to Alcon, there is no refit required for current Air Optix Aqua contact lens wearers. Find out more
- JOHNSON & JOHNSON OFFERS SIX-MONTH SUPPLY OF ACUVUE OASYS BRAND CLS, DISCONTINUES ACUVUE ADVANCE BRAND IN THE U.S. Johnson & Johnson Vision Care Inc.'s Acuvue Oasys Brand Contact Lenses are now available in a new six-month Supply Pack (12 lenses per box), which will replace all three-month Supply Packs (six lenses per box). The Acuvue Oasys six-month Supply Pack will be available in all parameters that are currently available in the current three-month and Annual Supply packs: power ranges of 8.4 and 8.8 BC including –0.50D to –6.00 in 0.25D steps, –6.50D to –12.00D in 0.50 steps, +0.50D to +6.00D in 0.25D steps, and +6.50D to +8.00D in 0.50D steps.
In other company news, Acuvue Advance Brand Contact Lenses, Acuvue Advance Brand for Astigmatism and Acuvue Advance Plus Brand will be discontinued effective March 31, 2015, and revenue lenses will no longer be available for sale from the company. Diagnostic lenses for Acuvue Advance Plus will be discontinued effective August 1, 2014. Additionally, all remaining parameters of Acuvue Brand Contact Lenses will also be discontinued on March 31, 2015. Johnson & Johnson Vision care will provide in-office tools to help doctors and staff transition patients from Acuvue Advance Brand Family and Acuvue Brand to the most current Acuvue technology. To ease the transition, the company is offering a Fitting Fee Reimbursement of up to $100 toward patients' fitting fees when Acuvue Advance Brand Family or Acuvue Brand wearers are prescribed an annual supply of any product in the Acuvue Oasys Brand Family, 1-Day Acuvue Moist Brand Family or 1-Day Acuvue TruEye Brand Contact Lenses. Stop by Johnson & Johnson's
website for more details.
- 300TH PATIENT ENROLLED IN CLINICAL STUDY OF LIGHT ADJUSTABLE LENS. Calhoun Vision has enrolled the 300th patient in the Phase III clinical study of its Light Adjustable Lens. The study, which is being conducted at 18 centers across the country, will include 600 patients, with 400 implanted with the LAL and 200 implanted with a monofocal control lens of the surgeon's choosing. According to Calhoun, its LAL technology is designed to allow surgeons to change and customize the power of the lens after it has been implanted in the eye. Patients return for one or two follow-up visits, during which the surgeon evaluates his vision and performs an adjustment to customize the shape and power of the lens by exposing it to ultraviolet light. Once the desired visual target is achieved, the surgeon locks in the lens with a final light treatment. Get more information at
- ECR PHARMACEUTICALS SOLD TO VALEANT PHARMACEUTICALS. In recent headlines, Akorn Inc. divested its subsidiary, ECR Pharmaceuticals, to Valeant Pharmaceuticals for $41 million in cash and assumption of certain liabilities. Click
here to read more.